摘要:
The invention provides methods and compositions for treating asthma and allergy by inhibiting VEGF expression and modulating the immune system from a Th2 response to a Th1 response.
摘要:
The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
摘要:
Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate internucleotide linkage and at least one alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, phosphoramidite, phosphate ester, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester internucleotide linkage.
摘要:
The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
摘要:
The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.
摘要:
Inhibition of replication of an infectious agent, gene expression of an infectious agent, or both, by administration of an oligonucleotide complementary to highly conserved regions of the infectious agent is described. Inhibition of replication of a virus, gene expression of a virus, or both, by administration of an oligonucleotide complementary to highly conserved regions of the virus is also described.
摘要:
Disclosed are synthetic oligonucleotides complementary to a transcript of the marORAB operon which inhibit expression of a gene in the operon. Also disclosed are methods of reducing bacterial resistance to antibiotics, and pharmaceutical formulations containing marORAB-specific oligonucleotides of the invention.
摘要:
The present invention provides a method of reducing the immunostimulatory effects of certain phosphorothioate oligonucleotides used to treat pathogen-mediated disease states and other medical conditions. Immunostimulatory effects of phosphorothioate oligonucleotides are reduced in accordance with the method of the invention by modifying at least one chemical structure within the phosphorothioate oligonucleotide to produce an immunostimulatory response-reducing phosphorothioate oligonucleotide, which is then administered to a mammal afflicted with the disease or condition being treated. The immune response of the mammal is also monitored in the method of the invention.
摘要:
This invention provides a novel compound for .sup.35 S-labelling oligonucleotides. The compound is .sup.35 S-3H-1,2-benzodithiol-3-one-1,1 dioxide (1) ##STR1## wherein the asterisk indicates the position of the .sup.35 S. Also provided is a method of synthesizing this compound, comprising first contacting .sup.35 S-thiobenzoic acid (4) with thiosalicylic acid (5) in acid medium to yield the condensation product, .sup.35 S-3 H 1,2-benzodithiol-3-one (2). .sup.35 S-3 H 1,2-benzodithiol-3-one (2) is then oxidized with a suitable oxidating agent such as trifuoroacetic acid and hydrogen perioxide to yield the desired product, .sup.35 S-3H-1,2-benzodithiol-3-one-1,1 dioxide (1). Any oligonucleotide susceptible to oxidative sulfurized by 3H-1,2-benzodithiol-3-one-1,1 dioxide can be labeled by .sup.35 S-3H-1,2-benzodithiol-3-one-1,1 dioxide (1). Accordingly, this invention also provides novel methods for .sup.35 S-labelling oligonucleotides. The compound and methods are useful for tracing biodistribution and degradation of antisense oligonucleotides in pharmacokinetic studies.
摘要翻译:本发明提供了一种用于35S标记寡核苷酸的新型化合物。 化合物是35S-3H-1,2-苯并二硫醇-3-酮二氧化物(1),其中星号表示35S的位置。 还提供了一种合成该化合物的方法,包括首先在酸性介质中将35S-硫代苯甲酸(4)与硫代水杨酸(5)接触以产生缩合产物,35S-3 H 1,2-苯并二硫酚-3-酮(2 )。 然后用合适的氧化剂如三氟乙酸和二氧化碳氧化35S-3 H 1,2-苯并二硫醇-3-酮(2),得到所需产物,35S-3H-1,2-苯并二硫醇-3-酮 -1二氧化物(1)。 任何对3H-1,2-苯并二硫酚-3-酮二氧化物进行氧化硫化的寡核苷酸可用35S-3H-1,2-苯并二硫酚-3-酮二氧化物(1)进行标记。 因此,本发明还提供了35S标记寡核苷酸的新方法。 该化合物和方法可用于在药代动力学研究中追踪反义寡核苷酸的生物分布和降解。
摘要:
Disclosed are synthetic oligonucleotides 15 to 50 nucleotides in length which are specifically hybridizable with at least a portion of RNA or DNA derived from the UL36, UL84, UL101x-102, or UL112-113 genes of a cytomegalovirus. Also disclosed are pharmaceutical compositions including an oligonucleotide of the invention and methods of inhibiting cytomegalovirus infection using such oligonucleotides.